Cargando…
Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension
Advances in technology and biomedical knowledge have led to the effective diagnosis and treatment of an increasing number of rare diseases. Pulmonary arterial hypertension (PAH) is a rare disorder of the pulmonary vasculature that is associated with high mortality and morbidity rates. Although signi...
Autores principales: | Ryanto, Gusty Rizky Teguh, Musthafa, Ahmad, Hara, Tetsuya, Emoto, Noriaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963072/ https://www.ncbi.nlm.nih.gov/pubmed/36834742 http://dx.doi.org/10.3390/ijms24043332 |
Ejemplares similares
-
Mitochondrial Dysfunction in Pulmonary Hypertension
por: Ryanto, Gusty Rizky Teguh, et al.
Publicado: (2023) -
Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going
por: Haryono, Andreas, et al.
Publicado: (2022) -
Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation
por: Suraya, Ratoe, et al.
Publicado: (2022) -
Increased serum activin A level in congenital heart disease‐associated pulmonary artery hypertension: A comparative study from the COHARD‐PH registry
por: Hadwiono, Muhammad R., et al.
Publicado: (2023) -
An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension
por: Ryanto, Gusty R. T., et al.
Publicado: (2021)